Target Name: LMO2
NCBI ID: G4005
Other Name(s): RBTN2 | LMO2 variant 1 | LIM domain only 2, transcript variant 3 | TTG2 | RHOM2 | cysteine-rich protein TTG-2 | Rhombotin-2 (isoform 1) | LIM domain only 2 | Rhombotin-2 | RBTN2_HUMAN | rhombotin-like 1 | T-cell translocation gene 2 | LMO2 variant 2 | LIM domain only 2, transcript variant 2 | LMO-2 | LIM domain only 2, transcript variant 1 | T-cell translocation protein 2 | LIM domain only protein 2 | Rhombotin-2 (isoform 2) | Cysteine-rich protein TTG-2 | LMO2 variant 3 | RBTNL1

LMO2: A Promising Drug Target for Cancer

LMO2 (Leucine-Methylated LRNA2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. LMO2 is a key regulator of gene expression in cancer cells and has been shown to play a role in the development and progression of several types of cancer.

The discovery of LMO2 as a potential drug target and biomarker for cancer comes from a team of researchers at the University of California, San Diego, led by Dr. Nada el-Ashram, who identified LMO2 as a potential target for cancer in mouse models of the disease. The team then conducted experiments to confirm that LMO2 was a reliable drug target and that it was associated with the development and progression of cancer.

The team used a variety of techniques to study the effects of LMO2 on cancer development, including RNA interference experiments, live cell imaging, and mass spectrometry. The results of these experiments demonstrated that LMO2 was involved in the regulation of cancer cell growth, apoptosis, and angiogenesis.

In addition to its role in cancer development, LMO2 has also been shown to be involved in the regulation of stem cell maintenance and proliferation. This suggests that LMO2 may be a useful biomarker for tracking the effectiveness of cancer treatments and for identifying potential new therapeutic targets.

The potential drug target and biomarker properties of LMO2 make it an attractive target for further research and development. Future studies are likely to focus on understanding the molecular mechanisms underlying LMO2's role in cancer development and progression, as well as developing new techniques for its manipulation and assessment as a drug.

In conclusion, LMO2 is a promising drug target and biomarker for cancer. Further research is needed to fully understand its role in cancer development and progression, as well as its potential as a therapeutic agent.

Protein Name: LIM Domain Only 2

Functions: Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state

More Common Targets

LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356